Display options
Cite
Della Bella S, Clerici M, Villa ML. Disarming dendritic cells: a tumor strategy to escape from immune control?. Expert Rev Clin Immunol. 2007;3(3):411-22doi: 10.1586/1744666X.3.3.411.
Della Bella, S., Clerici, M., & Villa, M. L. (2007). Disarming dendritic cells: a tumor strategy to escape from immune control?. Expert review of clinical immunology, 3(3), 411-22. https://doi.org/10.1586/1744666X.3.3.411
Della Bella, Silvia, et al. "Disarming dendritic cells: a tumor strategy to escape from immune control?." Expert review of clinical immunology vol. 3,3 (2007): 411-22. doi: https://doi.org/10.1586/1744666X.3.3.411
Della Bella S, Clerici M, Villa ML. Disarming dendritic cells: a tumor strategy to escape from immune control?. Expert Rev Clin Immunol. 2007 May;3(3):411-22. doi: 10.1586/1744666X.3.3.411. PMID: 20477683.
Copy Download .nbib Format: NLM
Share it on

Expert Rev Clin Immunol. 2007 May;3(3):411-22. doi: 10.1586/1744666X.3.3.411.

Disarming dendritic cells: a tumor strategy to escape from immune control?.

Expert review of clinical immunology

Silvia Della Bella, Mario Clerici, Maria Luisa Villa

Affiliations

  1. Università degli Studi di Milano, Laboratorio di Immunologia, Dipartimento di Scienze e Tecnologie Biomediche, LITA, via Fratelli Cervi 93, 20090 Segrate (Mi), Italy. [email protected]

PMID: 20477683 DOI: 10.1586/1744666X.3.3.411

Abstract

Although the immune system is clearly capable of recognizing and eliminating tumor cells, it usually fails to provide adequate protective antitumor responses. It is becoming increasingly clear that modifications of dendritic cells (DCs), which are central regulators of immune responses, could be a strategy exploited by tumor cells to escape from immune control. This review focuses on the current understanding of DC defects occurring in cancer patients, mechanisms responsible for the induction of such defects, consequences of DC defects on antitumor immune response and current concepts of DC-based immunotherapy. An improved understanding of how tumors interact with DCs to escape from immune control may enable the design of improved DC-based immunotherapeutic strategies for patients with cancer.

Publication Types